Amgen CEO says weight loss drug can address 'patient persistence issue'

Amgen CEO says weight loss drug can address 'patient persistence issue'
Amgen acquires Dark Blue Therapeutics for up to $840 million
CEO of drugmaker Amgen talks new results from cholesterol drug trial
🐾 Dogs of the Dow: Top 10 high-yield stocks for 2025 🐾 Ready to start 2025 with some high-yielding dividends? These Dogs of the Dow stocks are offering up to 6.8% yields! 📈 Here are the top 10 picks: - Verizon $VZ (6.79%) - Chevron $CVX (4.53%) - Amgen $AMGN (3.62%) -… https://t.co/DzcxZaFz5S https://t.co/QMeJT6CS7C
Amgen stock falls as analysts mull over weight loss drug’s bone density data
183.05BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US0311621009
CUSIP
031162100
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
23.75
PEG Ratio
2.23
Book Value
16.07
Dividend Share
9.52
Dividend Yield
2.80%
Earnings Share
14.23
Wall Street Target Price
352.73
EPS Estimate Current Year
22.32
EPS Estimate Next Year
23.36
EPS Estimate Current Quarter
4.7258
EPS Estimate Next Quarter
5.1808
Most Recent Quarter
-
Revenue TTM
36,750,999,552
Gross Profit TTM
26,013,999,104
EBITDA
16,616,999,936
Profit Margin
20.98%
Return On Assets TTM
7.93%
Return On Equity TTM
106.10%
Revenue Per Share TTM
68.31
Qtly Revenue Growth YOY
8.60%
Diluted Eps TTM
14.23
Qtly Earnings Growth YOY
112.10%
Trailing PE
23.75
Forward PE
15
Price Sales TTM
4.9581
Price Book MRQ
21.1424
Enterprise Value Revenue
6
Enterprise Value EBITDA
13
933.06
9.62%211.68
3.65%406.05
3.45%147.86
3.38%230.02
1.16%112.17
1.05%187.37
0.93%145.00
0.00%411.00
-1.95%50.15
-1.74%Curated watchlists where AMGN is featured.